Alkermes Adds Biopharma Veteran Anne Whitaker to Board
Event summary
- Alkermes appointed Anne C. Whitaker as an independent director to its Board on September 16, 2026.
- Whitaker brings extensive biopharmaceutical executive experience, including CEO roles at Aerami Therapeutics, Novoclem Therapeutics, and Synta Pharmaceuticals.
- She currently serves on the boards of Basilea Pharmaceutica and ICON plc, among other companies.
- Whitaker holds a B.S. in chemistry with a minor in business administration from the University of North Alabama.
The big picture
Alkermes' appointment of Anne Whitaker reflects a strategic move to bolster its board with deep biopharmaceutical experience amid a focus on neuroscience innovation. Whitaker's background in driving growth and transformation aligns with Alkermes' goals of addressing unmet needs in neuroscience and creating long-term shareholder value. The move underscores the company's commitment to leveraging executive expertise to navigate the competitive biopharmaceutical landscape.
What we're watching
- Strategic Alignment
- How Whitaker's experience in commercial and operational roles will influence Alkermes' pipeline and commercial strategy.
- Board Dynamics
- Whether Whitaker's diverse board experience will drive governance improvements or strategic pivots.
- Pipeline Progress
- The pace at which Alkermes advances its late-stage and early clinical candidates under Whitaker's guidance.